Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Healthpoint
ClinicalTrials.gov Identifier:
NCT01143727
First received: June 11, 2010
Last updated: November 5, 2012
Last verified: November 2012

June 11, 2010
November 5, 2012
July 2010
October 2011   (final data collection date for primary outcome measure)
Wound Appearance [ Time Frame: 28 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01143727 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers
Comparison of SANTYL vs. Hydrogel in Debridement of Inflamed Diabetic Foot Ulcers

This study compares two standard methods for cleaning the surface of wounds on the feet of patients with diabetes mellitus. The question being asked is whether inflammation of the wound affects the ability of one or both of the methods to work.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Diabetic Foot Ulcers
  • Drug: Santyl
    Apply one 24-hr period sufficient to cover the wound.
  • Drug: Tegaderm Hydrogel
    Apply once 24-hr period sufficient to cover the wound.
  • Active Comparator: A
    Santyl
    Intervention: Drug: Santyl
  • Active Comparator: B
    Tegaderm Hydrogel
    Intervention: Drug: Tegaderm Hydrogel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
October 2012
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The informed consent document must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting the screening visit. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart.
  • Of either sex, aged 18 years or older.
  • A diagnosis of Diabetes Mellitus, Type I or II, requiring medication to control blood glucose levels.
  • A qualifying ulcer, defined as follows:

    • Ulcer grade 1 or 2 on the Wagner Classification Scale (refer to Section 9.4.1)
    • Infection / inflammation grade 1 or 2 for wound bed inflammation (refer to Section 9.4.2)
    • Has not been treated or has not responded to treatment during the past 30 days
    • Has an apparent area ≥ 3.0 cm²
  • Requires debridement of the wound bed
  • Is sufficiently moist to allow collection of wound fluid using a filter paper disc
  • Adequate arterial blood flow evidenced by ankle brachial index (ABI) of ≥ 0.7 and ≤ 1.1; if the ABI is greater than 1.1, then toe pressure of >50 mmHg.
  • Subject must be willing to use the Darco shoe off-loading device and insole, or a comparable device, as indicated.
  • Subject able to follow instructions, particularly regarding the application of test articles and dressings at home. Able to apply the test articles, or has a caregiver available to apply the test articles according to the protocol.

Exclusion Criteria:

  • Contraindications or known hypersensitivity to the test articles or their components.
  • Cellulitis extending >2 cm around the target ulcer, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
  • Target ulcer tunneling per probing and visual assessment.
  • Use of systemic antibiotics or any drug listed in Section 9.1.6 of this protocol within 10 days of SCR visit.
  • Concomitant illness or condition which, in the opinion of the Principal - Investigator, places the subject at risk for this study.
  • The Medical Monitor may declare any subject ineligible for a valid procedural or medical reason.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01143727
017-101-09-025
No
Healthpoint
Healthpoint
Not Provided
Study Chair: Herbert B Slade, MD Healthpoint
Healthpoint
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP